JP2021524472A - 乾癬性関節炎の治療方法 - Google Patents

乾癬性関節炎の治療方法 Download PDF

Info

Publication number
JP2021524472A
JP2021524472A JP2020565417A JP2020565417A JP2021524472A JP 2021524472 A JP2021524472 A JP 2021524472A JP 2020565417 A JP2020565417 A JP 2020565417A JP 2020565417 A JP2020565417 A JP 2020565417A JP 2021524472 A JP2021524472 A JP 2021524472A
Authority
JP
Japan
Prior art keywords
compound
treatment
use according
psoriatic arthritis
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524472A5 (https=
JPWO2019224283A5 (https=
Inventor
ハリソン ピルレ
ハリソン ピルレ
メウレナーズ リュック
メウレナーズ リュック
テレセ タスセット チャンタル
テレセ タスセット チャンタル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2021524472A publication Critical patent/JP2021524472A/ja
Publication of JP2021524472A5 publication Critical patent/JP2021524472A5/ja
Publication of JPWO2019224283A5 publication Critical patent/JPWO2019224283A5/ja
Priority to JP2024021644A priority Critical patent/JP7751362B2/ja
Priority to JP2025157844A priority patent/JP2025183397A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020565417A 2018-05-24 2019-05-23 乾癬性関節炎の治療方法 Pending JP2021524472A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024021644A JP7751362B2 (ja) 2018-05-24 2024-02-16 乾癬性関節炎の治療方法
JP2025157844A JP2025183397A (ja) 2018-05-24 2025-09-24 乾癬性関節炎の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits
GB1808575.3 2018-05-24
PCT/EP2019/063283 WO2019224283A1 (en) 2018-05-24 2019-05-23 Methods for the treatment of psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024021644A Division JP7751362B2 (ja) 2018-05-24 2024-02-16 乾癬性関節炎の治療方法

Publications (3)

Publication Number Publication Date
JP2021524472A true JP2021524472A (ja) 2021-09-13
JP2021524472A5 JP2021524472A5 (https=) 2022-05-31
JPWO2019224283A5 JPWO2019224283A5 (https=) 2022-05-31

Family

ID=62812304

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020565417A Pending JP2021524472A (ja) 2018-05-24 2019-05-23 乾癬性関節炎の治療方法
JP2024021644A Active JP7751362B2 (ja) 2018-05-24 2024-02-16 乾癬性関節炎の治療方法
JP2025157844A Pending JP2025183397A (ja) 2018-05-24 2025-09-24 乾癬性関節炎の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024021644A Active JP7751362B2 (ja) 2018-05-24 2024-02-16 乾癬性関節炎の治療方法
JP2025157844A Pending JP2025183397A (ja) 2018-05-24 2025-09-24 乾癬性関節炎の治療方法

Country Status (9)

Country Link
US (2) US12329758B2 (https=)
EP (1) EP3801548A1 (https=)
JP (3) JP2021524472A (https=)
CN (1) CN112203660B (https=)
AU (2) AU2019273664B2 (https=)
CA (1) CA3101386A1 (https=)
GB (1) GB201808575D0 (https=)
MA (1) MA52738A (https=)
WO (1) WO2019224283A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP4178616A4 (en) * 2020-07-13 2024-07-24 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511620A (ja) * 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044722A1 (en) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JPWO2004039816A1 (ja) 2002-10-29 2006-03-02 塩野義製薬株式会社 セフェム化合物の無機酸塩の結晶
CA2515190A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010013768A1 (ja) 2008-07-31 2010-02-04 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AU2013279597B2 (en) 2012-06-22 2017-04-20 Alfasigma S.P.A. Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RS64677B1 (sr) 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
PL3595667T3 (pl) * 2017-03-14 2024-03-18 Galapagos Nv Kompozycje farmaceutyczne zawierające inhibitor jak

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511620A (ja) * 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.76, Suppl.2, JPN6023015678, 2017, pages 118 - 119, ISSN: 0005174847 *
ARTHRITIS AND RHEUMATOLOGY, vol. Vol.69, Suppl.10, JPN6023015679, 2017, pages 619, ISSN: 0005045189 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, JPN6023015680, 2014, pages 9323 - 9342, ISSN: 0005045190 *

Also Published As

Publication number Publication date
JP7751362B2 (ja) 2025-10-08
AU2019273664B2 (en) 2025-01-23
EP3801548A1 (en) 2021-04-14
KR20210013168A (ko) 2021-02-03
CN112203660A (zh) 2021-01-08
MA52738A (fr) 2021-04-14
US12329758B2 (en) 2025-06-17
CN112203660B (zh) 2024-12-31
AU2019273664A1 (en) 2021-01-21
US20210299135A1 (en) 2021-09-30
WO2019224283A1 (en) 2019-11-28
JP2025183397A (ja) 2025-12-16
GB201808575D0 (en) 2018-07-11
JP2024069223A (ja) 2024-05-21
US20260108530A1 (en) 2026-04-23
AU2025202777A1 (en) 2025-05-08
CA3101386A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EP3028702B1 (en) Methods of treatment using selective bcl-2 inhibitors
JP7751362B2 (ja) 乾癬性関節炎の治療方法
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220251105A1 (en) Methods of treating a mk2-mediated disorder
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US11780848B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
JP2023553534A (ja) 癌の処置のための併用療法
JP7547356B2 (ja) Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法
TW202126329A (zh) 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
JP2024516302A (ja) 結節性痒疹を治療するためのｊａｋ１経路阻害薬
JP2023515528A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法
CN114929227A (zh) 用乌帕替尼治疗脊柱关节炎和银屑病
KR102955500B1 (ko) 건선성 관절염의 치료 방법
Zhang et al. Preclinical characterization of the selective Jak1 inhibitor Lw402 for treatment of rheumatoid arthritis
TW202432117A (zh) 用於治療全身性硬化症之可溶性鳥苷酸環化酶活化劑
CN120957720A (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
JPWO2019224283A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231017